Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII

Journal of Clinical Oncology

Volumn 18, Issue 7, 2000, Pages 1412-1422

  Crivellari, Diana ^a   Bonetti, Marco ^b   Castiglione Gertsch, Monica ^b   Gelber, Richard D ^b   Rudenstam, Carl Magnus ^b   Thürlimann, Beat ^b   Price, Karen N ^b   Coates, Alan S ^b   Hürny, Christoph ^b   Bernhard, Jürg ^b   Lindtner, Jurij ^b   Collins, John ^b   Senn, Hans Jörg ^b   Cavalli, Franco ^b   Forbes, John ^b   Gudgeon, Anne ^b   Simoncini, Edda ^b   Cortes Funes, Hernan ^b   Veronesi, Andrea ^b   Fey, Martin ^b   Goldhirsch, Aron ^b   more..

^a Centro Oncologico Aviano   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LEUKOPENIA; LIVER TOXICITY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; MUCOSA INFLAMMATION; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME;

EID: 17044460539     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.7.1412     Document Type: Article

References (28)

1. Chu C, Tarone RE, Kessler LG, et al: Recent trends in U.S. breast cancer incidence, survival and mortality rates. J National Cancer Inst 88:1571-1579, 1996
2. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351:1451-1467, 1998
3. Castiglione M, Gelber RD, Goldhirsch A: Adjuvant systemic therapy for breast cancer in the elderly: Competing causes of mortality. J Clin Oncol 8:519-526, 1990
4. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials, 31,000 recurrences and 24,000 deaths among 75.000 women. Lancet 319:1-15, 71-84, 1992
5. Satariano WA, Ragland DR: The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 120:104-110, 1994
6. Taylor SG, Kalish LA, Olson JE, et al: Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal node-positive breast cancer patients: Three-year results of an Eastern Cooperative Oncology Group Study. J Clin Oncol 3:144-154, 1985
7. Goldhirsch A, Gelber R: Adjuvant treatment for early breast cancer: The Ludwig breast cancer studies. NCI Monogr 1:55-70, 1986
8. International Breast Cancer Study Group: Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 15:1385-1394, 1997
9. Hürny C, Bernhard J, Coates AS, et al: Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. Lancet 347:1279-1284, 1996
10. Bernhard J, Hürny C, Coates AS, et al: Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach. Ann Oncol 8:825-835,1997
11. Hollander M, Wolfe DA: Nonparametric Statistical Methods. New York, NY, John Wiley & Sons, 1973
12. Kendall M, Stuart A: The Advanced Theory of Statistics (vol 2). New York, NY, Macmillan Publishing Company Inc, 1979
13. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
14. Cox DR: Regression models and life-tables (with discussion). J R Stat Soc B (Methodol) 34:187-220, 1972
15. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
16. Colleoni M, Price KN, Castiglione-Gertsch M, et al: Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. Lancet 354:130-131, 1999
17. Gelman RS, Taylor SG: Cyclophsphamide, methotrexate, and fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 2:1404-1413, 1984
18. Bonadonna G, Valagussa P, Rossi A, et al: Ten-year experience with CMF based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5:95-115, 1985
19. Begg CB, Cohen JL, Ellerton J: Are the elderly predisposed to toxicity from cancer chemotherapy? An investigation using data from the Eastern Cooperative Oncology Group. Controlled Clin Trials 3:369-374, 1980
20. Christman K, Muss HB, Case LD, et al: Chemotherapy of metastatic breast cancer in the elderly: The Piedmont Oncology Association Experience. JAMA 268:57-62, 1992
21. Pritchard KI, Paterson AHC, Fine S, et al: Randomized trial of cyclophosphamide, methotrexate and fluorouracil chemotherapy in postmenopausal women with node-positive estrogen and/or progesterone receptor positive breast cancer: A report of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15: 2302-2311, 1997
22. Horan MA: Presentation of disease in old age, in Tallis R, Fillit H, Brocklehurst JC (eds): Textbook of Geriatric Medicine and Gerontology (ed 5). Churchill Livingstone, Edinburgh, United Kingdom, 1998
23. Cummings FJ, Gray R, Davis TE, et al: Tamoxifen versus placebo: Double blind adjuvant trial in elderly women with stage II breast cancer. NCI Monogr 1:119-123, 1986
24. Mouridsen HT, Andersen AP, Brincker H, et al: Adjuvant tamoxifen in postmenopausal high-risk breast cancer patients: Present status of Danish Breast Cancer Cooperative Group Trials. NCI Monograph 1:115-118, 1986
25. Butta A, MacLennon K, Flanders KC, et al: Induction of transforming growth factors in human breast cancer "in vivo" following tamoxifen. Cancer Res 52:4261-4264, 1992
26. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 352:930-942, 1998
27. Fisher B, Redmond C, Legault-Poisson S, et al: Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of node-positive breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8:1005-1018, 1990
28. Goldhirsch A, Coates AS, Colleoni M, et al: Adjuvant chemoendocrine therapy in postmenopausal breast cancer: Cyclophosphamide, methotrexate and fluorouracil dose and schedule may make a difference. J Clin Oncol 16:1358-1362, 1998